ALPINE IMMUNE SCIENCES, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Loss on sale of intangible asset
Total operating expenses

Loss from operations
Other income (expense):
Bargain purchase gain
Interest income
Interest expense
Other, net

Loss before taxes
Income tax (expense) benefit
Net loss
Comprehensive income (loss):
Unrealized gain (loss) on investments
Unrealized gain (loss) on foreign currency translation
Comprehensive loss
Weighted-average shares used to compute basic net loss per share (in shares)
Weighted-average shares used to compute diluted net loss per share (in shares)
Basic net loss per share (in dollars per share)
Diluted net loss per share (in dollars per share)

Comments